Citations

Clear

1792 citation(s) found for "Stephanie".

Outcomes in patients with DNA-damage repair related pancreatic cancer
Macklin, Sarah , Hines, Stephanie L., Kasi, Pashtoon Murtaza , Kasi, Pashtoon Murtaza

Mayo Clinic

No container title available | June 3, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.10012/v1 Get It

Abstract Background: Patients with DNA-damage response genes (DDR)-related pancreas cancer (BRCA1/2 or other DNA-damage related genes) may have improved outcomes secondary to increased sensitivity to DNA-damaging drugs (platinum chemotherapy/ poly ADP ribose polymerase (PARP)-inhibitors). However, data is scarce pertaining to outcomes in this subset of patients. Our objective was to retrospectively identify DDR-related pancreas cancer patients and report on clinical outcomes. Methods: Pancreas cancer patients with either a somatic or germline BRCA1/2 or other DDR genes were identified retrospectively through review of medical records (medical genetics/oncology), germline and tumor-based genetic testing results at our institution. Data regarding clinical outcomes, therapy received, and survival was subsequently extracted. Results: A total of 11 patients with pancreas cancer were identified. Pathogenic DDR-variants detected were within BRCA1 (3), ATM (4), BRCA2 (2), PALB2 (1) and FANCC (1). Five of these individuals had prior history of other cancers. Clinically these tumors were localized (4), locally advanced (3), and metastatic (4) at diagnosis. Seven out of 11 patients were still alive at time of data review. Survival in the 3 patients who had died in the metastatic/advanced cohort was 23.5, 25.8 and 111.5 months. All patients with advanced disease had exposure to platinum chemotherapy. Conclusions: Historical survival in patients with advanced and metastatic pancreas cancer is poor. Results of this DDR-subset of patients do show significantly superior outcomes, likely secondary to exposure to platinum drugs. This data, alongside other similar cohorts, would favor the DDR-genes being a predictive marker with improved survival if exposed to these drugs and the new class of drugs, PARP-inhibitors.
060 Women’s Perspectives on Aging and Menopause and Symptom Treatment
Kingsberg, Sheryl A. , Graham, S., Bernick, Brian , Mirkin, Sebastián, Faubion, Stephanie S. , Larkin, Lisa

Mayo Clinic

The Journal of Sexual Medicine | May 31, 2019 | Volume: 16 | Issue: Supplement_3 | Pages: S22-S23

10.1016/j.jsxm.2019.03.505 Get It

059 What are the Associations of Body Mass Index, Sexual Dysfunction and Mood in Midlife Women?
Fairbanks, Flávia, Kapoor, Ekta , Faubion, Stephanie S. , Mara, Kristin C.

Mayo Clinic

The Journal of Sexual Medicine | May 31, 2019 | Volume: 16 | Issue: Supplement_3 | Pages: S22-S22

10.1016/j.jsxm.2019.03.504 Get It

A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California
Lheureux, Stéphanie , Cristea, Mihaela , Mantia-Smaldone, Gina , Olawaiye, Alexander , Weberpals, Johanne I. , Hendrickson, Andrea E. Wahner , Welch, Stephen , Piskorz, Anna , Tan, Susie, Chang, Karen, Wang, Lisa , Kunos, Charles A., Cabanero, Michael , Ellard, Susan L. , Fleming, Gini F. , Dhani, Neesha C. , Chang, Karen, Pugh, Trevor J. , Brenton, James D. , Oza, Amit M.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 5518-5518

10.1200/jco.2019.37.15_suppl.5518 Get It

5518 Background: Platinum resistant ovarian cancer (OC) remains a therapeutic challenge. High grade serous OC (HGSOC) harbors TP53 mutations leading to increased dependency on S- and G2-phase checkpoints. Wee1 inhibition with Adavosertib (AZD 1775) (A) induces G2 checkpoint escape. Gemcitabine (G) is an antimetabolite therapy and blocks the progression of cells through the G1/S phase. We hypothesized that combining G+A would be synergistic and overcome resistance. Methods: We conducted a multicentre double-blind 2:1 randomized phase 2 trial to assess the progression free survival (PFS) in women with recurrent platinum-resistant/refractory HGSOC receiving G+A or G+placebo (P) (NCT02151292). Eligibility required measurable disease and feasibility of paired tumor biopsies; no limitation in prior lines of therapy. Non HGSOC histologic subtypes were enrolled in a separate non-randomized exploratory cohort. A/P was given orally at 175mg QD on D1-2, D8-9 and D15-16 with G 1000mg/m² IV D1, D8 and D15 in a 28-day cycle until progression or unacceptable AE. Tumor staging was scheduled every 8 weeks. TP53 mutations were analyzed on archival tissue with Sanger sequencing, TAm-Seq and IHC. TP53 mutation will be also assessed in circulating tumor DNA (ctDNA). Whole exome and RNA sequencing were performed on paired tumor tissues. Results: 124 patients (pts) with median of 3 prior lines of therapy (range 1-10) from 12 centres across Canada and US were enrolled between Sep 2014 to May 2018, with 99 pts randomized (65 in Arm G+A and 34 in G+P). 5 pts were ineligible; 64 pts have died. The median follow-up was 14.3 months. Main related AE was hematologic toxicity (Anemia G≥3: 31% in G+A vs 18% in G+P; Thrombocytopenia G≥3: 31% vs 6%; Neutropenia G≥3: 62% vs 30%). PFS was significantly improved from 3.0 to 4.6 months (HR 0.56 (95%CI: 0.35-0.90, p=0.015 Log rank). There was a significant improvement in overall survival (OS) from 7.2 to 11.5 months (HR 0.56 (95%CI: 0.34-0.92, P=0.022). Partial response by RECIST 1.1 was observed in 13 (21%) and 1 (3%) pts for Arms G+A and G+P, respectively (p=0.02). From the 25 pts in the exploratory cohort, 3 (12%) partial responses were observed. Final results will be reported at the meeting. Conclusion: Addition of adavosertib to gemcitabine in women with platinum resistant/refractory OC improved response rate, PFS and OS with manageable toxicity. Clinical trial information: NCT02151292.
Racial and ethnic differences in the results of multigene panel testing of inherited cancer predisposition genes in breast cancer patients.
Yadav, Siddhartha , LaDuca, Holly , Niguidula, Nancy , Lilyquist, Jenna , Gutierrez, Stephanie, Yussuf, Amal , Davis, Brigette Tippin, Pesaran, Tina , Goldgar, David E. , Dolinsky, Jill S. , Yadav, Siddhartha , Polley, Eric C. , Shimelis, Hermela , Hu, Chunling , Na, Jie , Lee, Kun Hee , Hart, Steven N. , Chao, Elizabeth , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 1514-1514

10.1200/jco.2019.37.15_suppl.1514 Get It

1514 Background: The prevalence of germline mutations in non-white patients with breast cancer and the germline genetic drivers of breast cancer risk in non-white populations are largely unknown. Methods: The study population included 77,900 women with breast cancer (Non-Hispanic white: 57,003; Black: 6,722; Asian: 4,183; Hispanic: 5,194; Ashkenazi-Jewish: 4,798) who underwent germline multigene panel testing of cancer predisposition genes from March 2012 to December 2016. The prevalence of predisposition gene mutations in racial and ethnic populations relative to non-Hispanic Whites was assessed while accounting for age at diagnosis of breast cancer, family history of breast and ovarian cancer, and estrogen receptor status of breast tumors. Associations between mutations in each gene and breast cancer risk were evaluated using reference controls. Results: The overall frequency of pathogenic mutations in known breast cancer predisposition genes was 9.1% for non-Hispanic Whites, 9.8% for African Americans, 10.2% for Hispanics, 7.6% for Ashkenazi-Jewish, and 7.5% for Asians. BRCA1 mutations were enriched (p < 0.05) and CHEK2 mutations were under-represented in all racial and ethnic populations relative to non-Hispanic Whites. BRCA2 and BARD1 mutations were enriched in African Americans and Hispanics relative to non-Hispanic Whites, whereas PALB2 and RAD51C mutations were enriched in Hispanics. Among genes with mutation counts large enough for assessment, mutations in BARD1, BRCA1, BRCA2, PALB2 and TP53 were significantly associated with clinically relevant increased risks (odds ratio (OR) > 2) of breast cancer across all ethnicities and races. Rates of variants of uncertain significance were highest among Asians (29%), followed by blacks (27%), Hispanics (21%), non-Hispanic whites (16%) and Ashkenazi-Jews (14%). Conclusions: While there is some similarity across ethnic groups, substantial heterogeneity exists in the prevalence of mutations in breast cancer predisposition genes across major racial and ethnic groups in the US population. These findings contribute to our understanding of breast cancer risk and have significant implications for genetic testing, screening, and management of patients with an inherited predisposition to breast cancer, with a need for continued analysis with increased cohort size in ethnic minority groups.
Rethinking the Cost of High-Value Care
Starr, Stephanie R. , Agrwal, Neera , Hunderfund, Andrea N. Leep

Mayo Clinic

Academic Medicine | May 24, 2019 | Volume: 94 | Issue: 6 | Pages: 747-747

10.1097/acm.0000000000002683 | PMID 31136337 Get It

Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019
Brown, Patrick A. , Wieduwilt, Matthew J. , Wang, Eunice S. , Fathi, Amir T. , Litzow, Mark R. , Aoun, Patricia, Bhatnagar, Bhavana , Boyer, Michael W., Bryan, Teresa , Burke, Patrick W. , Coccia, Peter F., Coutré, Steven , Kirby, Suzanne, Massaro, Stephanie, Mattison, Ryan J. , Oluwole, Olalekan O. , Papadantonakis, Nikolaos , Park, Jae H. , Uy, Geoffrey L. , Gregory, Kristina M., Ogba, Ndiya , Wang, Eunice S. , Oluwole, Olalekan O , Uy, Geoffrey , Logan, Aaron C , DeAngelo, Daniel J. , Cassaday, Ryan D. , Advani, Anjali S. , Jain, Nitin , Liu, Arthur , Rubnitz, Jeffrey E. , Shah, Bijal

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 22, 2019 | Volume: 17 | Issue: 5 | Pages: 414-423

10.6004/jnccn.2019.0024 | PMID 31085755 Get It

Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.
Resolution of Postsurgical Diplopia, Paresthesia, and Weakness Following Inpatient Massage Therapy: A Case Report
Hauschulz, Jennifer L. , Clark, Stephanie , Bauer, Brent A. , Chon, Tony Y. , Hauschulz, Jennifer , Bauer, Brent, Chon, Tony

Mayo Clinic

Global Advances in Health and Medicine | May 16, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2164956119852396 | PMID 31192054 Get It

Massage therapy is utilized in hospitals for patients experiencing pain, anxiety, sleeplessness, among other symptoms. Postsurgical pain is one of the most common reasons massage therapy is ordered. We present a case of a 45-year-old woman who underwent ventral hernia repair. Postoperative day 2, she began to experience multiple symptoms, including double-vision, left-sided facial numbness, tremors, pain, and weakness in her left fingers, arm, and leg. A static magnetic resonance image of the brain and cervical spine were obtained, which revealed disc protrusions at C3/C4, C5/C6, C6/C7, and mild deformity of the spinal cord. The patient’s pain was difficult to control and she was unable to be weaned from intravenous pain medication. Massage therapy was ordered on postoperative days 6 and 7. During both massage sessions, as upper neck muscle tension was reduced, the therapist and patient observed several audible “pops” of the cervical spine with immediate relief of symptoms. In this particular case, massage therapy, though requested to address pain, had a secondary benefit in relieving her diplopia, left-sided facial numbness, tremors, and weakness. Although the mechanism of action is not clear, this case highlights the significant secondary beneficial effects that often occur with massage therapy.
Genomic Observations of a Rare/Pathogenic SMAD3 Variant in Loeys–Dietz Syndrome 3 Confirmed by Protein Informatics and Structural Investigations
Richter, John E. , Samreen, Ayesha , Vadlamudi, Charitha , Helmi, Haytham , Mohammad, Ahmed N. , Wierenga, Klaas J. , Hines, Stephanie L., Caulfield, Thomas R. , Wierenga, Klaas, Hines, Stephanie, Caulfield, Thomas R , Samreen, Ayesha , Atwal, Paldeep S

Mayo Clinic

Medicina | May 15, 2019 | Volume: 55 | Issue: 5 | Pages: 137

10.3390/medicina55050137 | PMID 31096651 Get It

Background and objectives: Loeys–Dietz syndrome 3, also known as aneurysms-–osteoarthritis syndrome, is an autosomal dominant genetic connective tissue disease caused by pathogenic variants in SMAD3, a transcription factor involved in TGF-β signaling. This disorder is characterized by early-onset osteoarthritis and arterial aneurysms. Common features include scoliosis, uvula abnormalities, striae, and velvety skin. Materials and Methods: The pathogenicity of a variant of uncertain significance in the SMAD3 gene was evaluated (variant c.220C > T) through personalized protein informatics and molecular studies. Results: The case of a 44-year-old male, who was originally presumed to have Marfan syndrome, is presented. An expanded gene panel determined the probable cause to be a variant in SMAD3, c.220C > T (p.R74W). His case was complicated by a history of stroke, but his phenotype was otherwise characteristic for Loeys–Dietz syndrome 3. Conclusion: This case emphasizes the importance of comprehensive genetic testing to evaluate patients for connective tissue disorders, as well as the potential benefit of utilizing a protein informatics platform for the assessment of variant pathogenicity.
Sexual function after cancer: paying the price of survivorship
Kingsberg, Sheryl A. , Bober, Sharon L. , Faubion, Stephanie S.

Mayo Clinic

Climacteric | May 15, 2019 | Volume: 22 | Issue: 6 | Pages: 558-564

10.1080/13697137.2019.1606796 | PMID 31090466 Get It